Issue of Treasury Shares to the Company
Faron Pharmaceuticals Ltd. announced the Board of Directors has resolved to issue 21,469,427 treasury shares to itself without consideration, expected to be registered by June 10, 2026, to prepare for future bond conversions. These shares will be admitted to trading on Nasdaq First North Growth Market Finland and AIM, with trading commencing around June 11, 2026. Following this, the company will have an aggregate of 224,514,938 shares, with 25,000,000 held in treasury, compared to the current 203,045,511 shares and 3,530,573 treasury shares.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | May 28, 2026 at 15:35:00 EEST |
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board of Directors of Faron (the “Board”) has resolved to issue 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds.
The 21,469,427 treasury shares issued to the Company itself are expected to be registered in the Finnish Trade Register on or around 10 June 2026. The treasury shares will rank pari passu in all respects with the existing shares of the Company once they are registered with the Finnish Trade Register and further conveyed from treasury.
The Company will make applications for the admission of the newly issued treasury shares to trading on shares on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“) with said admissions expected to become effective and trading to commence on or around 11 June 2026 (the “Admissions”).
Following the registration, the aggregate number of shares in the Company is 224,514,938 and of these shares, the Company will hold 25,000,000 in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. On the date of this announcement, the aggregate number of shares in the Company is 203,045,511 and of these shares the Company holds 3,530,573 in treasury.
About Bexmarilimab
About Faron Pharmaceuticals Ltd.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.